PRRT2 and neoplasm: Notably, mTORC1 inhibitors like rapamycin, despite their potency, carry risks of immunosuppression and have shown limited brain exposure in clinical settings [36,37]; PKC agonists (e.g., PMA), which are tumor-promoting and therapeutically unsuitable; and natural products such as trehalose, which exhibit weak potency (∼100 mM) despite proposed mechanisms like AKT inhibition [38].